Shots:

• Gustave Roussy to receive funding and support from Daiichi Sankyo for integrative research program including clinical- translational- and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer respectively
• The research program includes two P-II studies evaluating the efficacy- safety- and markers of response and resistance to DS-1062 & patritumab deruxtecan in patients with advanced NSCLC- progressed on anti-PD-1/PD-L1 therapy and Pt-doublet CT & HER3 expressing mBC respectively
• Each study will enroll ~100 patients and will be conducted at several sites in France. The 1EPs of the studies will be ORR and 2EPs includes clinical benefit rate- PFS- DoR- OS- and safety measures. DS-1062 is a TROP2 directed DXd ADC while patritumab deruxtecan is a HER3 directed DXd ADC

  Ref: Daiichi Sankyo| Image: ETHealthworld